rezlidhia
rezlidhia: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | Approved |
FDA Decisions
Frequently asked questions
Who is developing rezlidhia?
rezlidhia is being developed by RIGEL PHARMACEUTICALS INC.
What is rezlidhia's latest FDA decision?
The most recent tracked FDA decision for rezlidhia is Approval for 1 INDICATIONS AND USAGE Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.1 )] . REZLIDHIA is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with , dated December 1, 2022.
Get deeper analysis on rezlidhia
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis